Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XC32
|
| gptkbp:brand |
gptkb:Poteligeo
|
| gptkbp:CASNumber |
1008201-43-6
|
| gptkbp:developer |
gptkb:Kyowa_Kirin
|
| gptkbp:form |
solution for infusion
|
| gptkbp:genericName |
mogamulizumab
|
| gptkbp:indication |
gptkb:leukemia
relapsed or refractory Sézary syndrome relapsed or refractory mycosis fungoides |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:monoclonal_antibody
|
| gptkbp:mechanismOfAction |
anti-CCR4 monoclonal antibody
|
| gptkbp:PregnancyCategory |
not assigned
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
diarrhea
fatigue infections rash musculoskeletal pain infusion reaction |
| gptkbp:target |
gptkb:CCR4
|
| gptkbp:UNII |
6QY1D43K5B
|
| gptkbp:usedFor |
gptkb:mycosis_fungoides
gptkb:Sézary_syndrome |
| gptkbp:bfsParent |
gptkb:Kyowa_Kirin
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Poteligeo
|